
## Jean M Elwing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/573945/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 198-207.	2.5	32
2	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulmonary Circulation, 2017, 7, 167-174.	0.8	29
3	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
4	Chronic Thromboembolic Pulmonary Hypertension. Clinics in Chest Medicine, 2018, 39, 605-620.	0.8	19
5	Interhospital Transfer of Patients With Acute Pulmonary Embolism. Chest, 2021, 160, 1844-1852.	0.4	19
6	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2021, 11, 1-10.	0.8	17
7	Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension. Liver Transplantation, 2021, 27, 1811-1823.	1.3	16
8	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.3	15
9	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation, 2022, 12, e12055.	0.8	6
10	Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulmonary Circulation, 2019, 9, 1-12.	0.8	5
11	Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naÃ <sup>-</sup> ve pulmonary hypertension. European Journal of Radiology, 2020, 123, 108784.	1.2	5
12	Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis. Respiratory Medicine, 2021, 190, 106683.	1.3	5
13	Utilization of risk assessment tools in management of PAH: A PAH provider survey. Pulmonary Circulation, 2022, 12, e12057.	0.8	4
14	Predictive value of incidental right ventricular abnormalities identified on SPECT for mortality and pulmonary hypertension. Journal of Nuclear Cardiology, 2022, 29, 1903-1914.	1.4	3
15	Healthâ€related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). Pulmonary Circulation, 2021, 11, 1-11.	0.8	3
16	A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma. Case Reports in Rheumatology, 2016, 2016, 1-4.	0.2	2
17	Improving adherence to pulmonary hypertension screening in patients with systemic sclerosis: Overcoming the provider-level barriers. Journal of Scleroderma and Related Disorders, 2020, 5, 219-223.	1.0	1
18	An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101979.	1.1	1

#	Article	IF	CITATIONS
19	Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy. BMJ Case Reports, 2021, 14, .	0.2	ο